deltatrials
Completed PHASE3 NCT00349622

Clinical Trial Ceftriaxone in Subjects With ALS

Clinical Trial Ceftriaxone in Subjects With Amyotrophic Lateral Sclerosis (ALS)

Sponsor: Massachusetts General Hospital

Conditions ALS Amyotrophic Lateral Sclerosis
Interventions ceftriaxone placebo
Updated 7 times since 2017 Last updated: Apr 1, 2014 Started: Jul 31, 2006 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

Listed as NCT00349622, this PHASE3 trial focuses on ALS and Amyotrophic Lateral Sclerosis and remains completed. Sponsored by Massachusetts General Hospital, it has been updated 7 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Massachusetts General Hospital
  • National Institute of Neurological Disorders and Stroke (NINDS)
Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Atlanta, United States, Augusta, United States, Aurora, United States, Boston, United States, Burlington, United States, Calgary, Canada, Charleston, United States, Charlotte, United States, Charlottesville, United States and 40 more location s